Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Progress in treating heart disease, cancer and stroke were helping to drive the improvement in Americans' life expectancy before the opioid crisis sent it tumbling, according to a new study in Health Affairs.

By the numbers: From 1990 to 2015, Americans' average life expectancy rose by 3.3 years. The study attributes 1.76 years of that improvement to reduced mortality from heart disease, 0.34 years from lung cancer and 0.33 years to improved care for stroke.

Between the lines: This is what's supposed to happen — advancements in care and better public-health awareness are supposed to help life expectancy tick up every year.

  • In the years just after this study cuts off, though — beginning in 2015 — American life expectancy declined for four years in a row, for the first time in decades, because of the opioid epidemic.
  • It began to rebound again in 2018, according to CDC data.

Go deeper

Caitlin Owens, author of Vitals
Oct 21, 2020 - Health

The overwhelming aftershocks of the pandemic

Illustration: Eniola Odetunde/Axios

The coronavirus pandemic will wreak havoc on the U.S. health care system long after it ends — whenever that may be.

Why it matters: The pre-pandemic health care system was already full of holes, many of which have been exposed and exacerbated over the past several months, and many Americans will be stuck with that system as they grapple with the long-term consequences of the pandemic.

Barr appoints special counsel to continue investigating origins of Russia probe

Photo: Mandel Ngan/AFP via Getty Images

Attorney General Bill Barr told the AP on Tuesday he appointed veteran prosecutor John Durham as a special counsel on Oct. 19 to continue investigating the origins of the FBI's 2016 probe into possible coordination between the Trump campaign and Russia.

Why it matters: It's an extra layer of protection for Durham to continue investigating possible misconduct by Obama-era intelligence officials past Joe Biden's inauguration as president.

7 mins ago - Podcasts

Nasdaq exec Jeff Thomas on new diversity rules for listed companies

The Nasdaq today said it will ask federal securities regulators to approve new rules that would require its listed companies to regularly report on the demographic diversity of their boards, and also comply with board diversity requirements.

Axios Re:Cap goes deeper with Jeff Thomas, Nasdaq's senior VP of corporate services, to learn why Nasdaq is enacting this policy, the internal discussions that led to it and what happens to companies that don't comply.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!